In regard to treating MD, while invasive approaches (e.g., intravitreal anti-vascular endothelial growth factor agents, Ammar et al., 2020) are used to counteract the effects of the exudative form of MD (Wet AMD), no current standard intervention exists for the progressive type of MD (dry MD), which accounts for 85% of the cases (Jager et al., 2008). Here, VEGFA is linked to Menkes disease.